Driven by the vital need to develop better therapies for Advanced Heart Failure

Welcome to LoneStar Heart, Inc.

LoneStar Heart, Inc. is a disease-focused company developing breakthrough therapies to preserve and restore adequate heart function in patients with Advanced Heart Failure (HF), a condition that affects millions of ageing patients worldwide. Applying the latest insights from bioengineering, mathematical modeling, molecular biology, and clinical research, the company is advancing a number of product candidates that combine practical and cost-effective solutions with superior clinical outcomes.

Algisyl has obtained the CE Mark and is currently available for sale in Europe. Algisyl is not approved by the FDA for sale in the USA at this time.